Artis BioSolutions published a piece on ChEnected, AIChE - American Institute of Chemical Engineers, discussing technologies compressing drug development timelines.

Advanced Therapies Are Only as Strong as the Materials Used to Create Them As the first company to combine proprietary synthetic DNA manufacturing with advanced therapy development and GMP manufacturing, Artis provides a connected path from starting material to clinical production. Our integrated platform helps genetic medicine developers move faster, reduce complexity, and maintain greater control throughout development. With operations in the United States and Europe, Artis supports programs spanning cell therapy, gene therapy, mRNA, gene editing, vaccines, and other advanced therapeutic modalities. By bringing synthetic DNA, process development, and GMP manufacturing together under one organization, we help transform promising science into clinical reality.